Pfizer Sued by Australian Regulator Over Generic Lipitor
This article is for subscribers only.
Pfizer Inc.’s Australian unit was sued by the country’s competition regulator for misuse of market power relating to sales of its generic version of the Lipitor cholesterol drug.
The Australian Competition and Consumer Commission said it filed the lawsuit today in federal court in Sydney claiming Pfizer Australia Pty.’s deals with pharmacies in 2012 for the sale of atorvastatin breached competition rules. A copy of the filing wasn’t immediately available.